SCHEMBL8556483

SCHEMBL8556483

CON=C(C(=O)Oc1ccc(OC(C)c2nc3ccccc3[nH]2)cc1)c1ccc(OC(C)c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.45
NPC1 O15118 4/20 0.45
KLF5 Q13887 1/20 0.45
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 3/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
GAA P10253 1/20 0.39
IDO1 P14902 1/20 0.38
THRB P10828 1/20 0.37
MLKL Q8NB16 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5530550 0.80 RAB9A (0.58) RAB9ANPC1KLF5LMNASMN1; SMN2
SCHEMBL5532731 0.80 NPC1 (0.54) RAB9ANPC1KLF5LMNASMN1; SMN2
SCHEMBL5515761 0.77 RAB9A (0.48) RAB9ANPC1KLF5LMNASMN1; SMN2
SCHEMBL5517429 0.72 RAB9A (0.46) RAB9ANPC1KLF5LMNASMN1; SMN2
SCHEMBL8558701 0.71 LMNA (0.43) RAB9ANPC1KLF5LMNASMN1; SMN2
SCHEMBL9427792 0.70 MLKL (0.53) RAB9ANPC1KLF5LMNASMN1; SMN2
SCHEMBL5443699 0.69 PPARA (0.48) RAB9ANPC1LMNASMN1; SMN2L3MBTL1
SCHEMBL27447670 0.69 ELANE (0.45) RAB9ANPC1L3MBTL1PKMKMT2A
SCHEMBL8557020 0.68 GPBAR1 (0.46) RAB9ANPC1SMN1; SMN2KMT2ANFKB1
SCHEMBL7596328 0.68 KMT2A (0.47) RAB9ANPC1KLF5LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5714488-A FOR TREATMENT OF ALLERGIC AND INFLAMMATORY DISEASE STATES ABBOTT LABORATORIES (US) 1998-02-03 US disclosed